Crossmark

Adjuvant chemotherapy for pT1-3N0-1 breast cancer patients with HR+, HER2− subtype: a propensity-score matched study with competing risk analysis

Published Online: 2023-07-14

Published Print: 2023-11

Authors

Dong, Hong

Su, Xinyu

Li, Xun

Fu, Peng

Tan, Lun
Funding

Funding for this research was provided by:

Health Commission of Hubei Province (WJ2019H396)
License Information

Text and Data Mining valid from 2023-07-14

Version of Record valid from 2023-07-14
More Information

Article History

Received: 2 June 2023

Accepted: 4 July 2023

First Online: 14 July 2023

Declarations

:

: None declared.

Document is current